|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide显示文摘AIM: To evaluate prospectively immediate intraocular pressure (IOP) changes after the intravitreal injection of ranibizumab, 2 and 4mg triamcinolone acetonide. METHODS: Patients who underwent intravitreal injection of 0.1mL (4mg) triamcinolone acetonide (TA, Group T4), 0.05mL (2mg) TA (Group T2) and 0.05mL (0.5mg) ranibizumab (Group R) comprised the study population. Overall, 229 eyes of 205 patients were injected. Fifty-four eyes (23.6%) were in Group T4, 69 eyes (30.1%) in Group T2 and 106 eyes (46.3%) in Group R. If IOP was less than 26mmHg immediately after the injection no further measurement was performed. If IOP was ≥26mmHg, IOP was remeasured till the reading was below 26mmHg at 5, 15 and 30 minutes. RESULTS: Immediately after the injection, the IOP of 28 eyes (51.9%) in Group T4, 22 eyes (31.9%) in Group T2 and 51 eyes (48.1%) in Group R were over 25mmHg. At 30 minutes, IOP of one eye (1.9%) in group T4, two eyes (2.9%) in group T2 and two eyes (1.9 %) in Group R were over 25mmHg. Immediate post-injection IOP was significantly higher in Group T4 and Group R when compared to Group T2 (P <0.001 and P <0.001, respectively). IOP was significantly higher in eyes without vitreous reflux when compared to those with vitreous reflux in all groups (P <0.001). CONCLUSION: IOP may remarkably increase immediately after the intravitreal injection of 2 or 4mg triamcinolone acetonide, and 0.5mg ranibizumab. Absence of vitreous reflux is the most important predicting factor for immediate IOP rise after the injection. | Gul Arikan Ali Osman Saatci Ferit Hakan Oner | 2011 | International Journal of Ophthalmology(English edition)2011，4，4： | 6 |
| 2 | 匹克威克综合征和阻塞性睡眠呼吸暂停综合征相关性假性脑瘤(英文)显示文摘目的:报告1例男性患者合并有匹克威克综合征和阻塞性睡眠呼吸暂停(OSA),其临床表现为假性脑瘤和视力下降。方法:病例报告。结果:患者,男,54岁,过度肥胖,诉双眼视力渐降3mo,检查示:视力:右眼20/200,左眼20/400,左眼合并色觉异常,眼底镜示双视乳头水肿和视盘旁出血,左眼合并黄斑部渗出。体格检查和实验室检查符合阻塞性睡眠呼吸暂停与匹克威克综合征诊断。腰椎穿刺:开放压350mmHg,脑部扫描正常。诊断:OSA和匹克威克综合征相关性假性脑瘤。眼底表现和视力随采血治疗、血压控制、体重控制及双层正压通气治疗而改善。结论:对于患有假性脑瘤的患者,必须对阻塞性睡眠呼吸暂停与匹克威克综合征有所警惕。 | Ozlem Barut Selver Meltem Soylev Bajin Oya Itil Ali Osman Saatci | 2011 | 国际眼科杂志2011，11，4： | 5 |
| 3 | Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema显示文摘Diabetic macular edema(DME)is a very important and well-known cause of visual loss in diabetics.Blood-retina barrier disruption and consequent intraretinal fluid accumulation may lead to retinal thickening at the posterior pole namely DME.Even though it is not clearly understood,current evidence suggests that chronic low-grade inflammation characterized with various cytokines has a major role in the occurrence of DME.Clinical trials are continuously shaping our treatment approaches for the eyes with DME.Today,vascular endothelial growth factor(VEGF)inhibitor and steroid administrations are the main alternatives in DME treatment.Dexamethasone(DEX)implant(Ozurdex®;Allergan,Inc.,Irvine,CA,United States)was approved by the United States Food&Drug Administration in 2014 for DME treatment.The implant is made up of a biodegradable solid copolymer that is broken down by releasing its active ingredient into the vitreous cavity over time.Biphasic release feature of this sustained-release drug delivery system ensures its efficacy for up to 6 mo with an acceptable and manageable safety profile.DEX implant provides a favorable anatomical and functional outcome in DME as shown in several randomized-controlled studies but has a relatively higher ocular side-effect profile such as increased risk of cataract formation and raised intraocular pressure when compared to the gold standard anti-VEGF agents.Thus,DEX implant becomes the second-line treatment option demonstrating inadequate clinical response to anti-VEGF therapy.However,it can be preferred as the first-line treatment in vitrectomized and pseudophakic eyes.Even in some selected conditions DEX implant is favored over anti-VEGF agents where the use of VEGF-inhibitors is either inappropriate or contraindicated such as the patients with a recent history of a major cardiovascular or cerebrovascular event,pregnancy and noncompliant to frequent visits.This mini-review briefly overviews the efficacy,safety profile and complications of DEX implant and summarizes the outcome of DEX implant administration in major clinical studies on DME treatment. | Omer Karti Ali Osman Saatci | 2021 | World Journal of Diabetes2021，12，8： | 2 |
| 4 | Endovascular parent artery occlusion in large-gaint or fusiform dital posterior cerebral artery aneurysms显示文摘 | Arat A Isalak C Saatci I | 2002 | Neuroradiology2002，44，8： | 1 |
| 5 | Gadodiamide as an alternative contrast medium in cerebral angiography in a patient with sensitivity to iodinated contrast medium显示文摘 | Arat A Cekirge HS Saatci I | 2000 | Neuroradiology2000，42，： | 1 |
| 6 | Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy in dialyzed children显示文摘 | Baskin E Besbas N Saatci U | 2004 | Turk J Pediatr2004，46，1： | 1 |
| 7 | A New Classificalion for Cochleovestibular Malformations显示文摘 | Sennaroglu L Saatci I | 2002 | Laryngoscope2002，112，12： | 1 |
| 8 | Endovascular treatment of brain artefio- venous malformations with prolonged intranidal Onyx injection technique: long-term results in 350 consecutive patients with completed endovascular treatment course显示文摘 | Saatci I Geylk S Yavuz K | 2011 | J Neurosurg2011，115，1： | 1 |
| 9 | Granial MR findings in Wilson's disease显示文摘 | Topcu M Baltaoglu FF | 1997 | Acta Radial1997，38，： | 1 |
| 10 | Treatment of internal carotid artery aneurysms with a covered stent:experience in 24 patients with mid-term follow-up results显示文摘 | Saatci I Cekirge HS Ozturk MH | 2004 | AJNR2004，25，： | 1 |
| 11 | A new classification for cochleovestibularmalformations显示文摘 | Sennaroqglu L Saatci I | 2002 | Laryngoscope2002，112，12： | 1 |
| 12 | Posterior chamber intraocular lens implantation in eyes with inactive and active proliferative diabetic retinopathy显示文摘 | Ruiz RS Saatci OA | 1991 | Am J Ophthalmol1991，111，2： | 1 |
| 13 | Severe iron deficiency anenia in a child with idiopathic pulmonary hemosiderosis:a case report 显示文摘 | Derbent M Ozcay F Saatci U Ozbek N | 2002 | Turk J Pediatr2002，44，3： | 1 |
| 14 | A new classification for cochleovestibular malformations显示文摘 | Sennaroglu L Saatci I | 2002 | Laryngoscope2002，112，： | 1 |
| 15 | Vasculitis and expression of vascular cell adhesion molecule-1,intercellular adhesion molecule-1,and E-selectin in salivary glands of patients with Sjogren's syndrome显示文摘 | Turkcapar N Sak SD Saatci M | 2005 | J Rheumatol2005，32，6： | 1 |
| 16 | A New Classfication for Cochleovestibular Malformations显示文摘 | Sennaroglu L Saatci I | 2002 | Laryngoscope2002，112，12： | 1 |
| 17 | Evaluation of the treatment changes of functional posterior crossbite in the mixed dentition 显示文摘 | Kecik D Kocadereli I Saatci I | 2007 | Am J Orthod Dentofacial Orthop2007，131，2： | 1 |
| 18 | Endovaacular treatment of brain ar- teriovenous malformations with prolonged intranidal Onyx injec- tion technique: long-term results in 350 consecutive patients with completed endovascular Ireatment course 显示文摘 | Saatci I Geyik S Yavuz K | 2011 | J Neurosurg2011，115，1： | 1 |
| 19 | A new classification for cochleovestibula malformations显示文摘 | SENNAROGLU L SAATCI I | 2002 | Laryngoscope2002，112，： | 1 |
| 20 | Treatment of internal carotid artery aneurysms with a covered stent:experience in 24 patients with mid-term follow-up results显示文摘 | Saatci I Cekirge HS Ozturk MH | 2004 | AJNR Am J Neuroradiol2004，25，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员